Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
Authors:
- 3 July 2020
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 19 (8) , 1592-1601.e3
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
- Shire
- National Center for Advancing Translational Sciences
- Celgene
- AbbVie
- Crohn's and Colitis Foundation (370763, UL1 TR000448)
- Genentech
- Alvin J. Siteman Cancer Center (P30-CA091842, UL1TR001105)
- National Institutes of Health (K23KD111995-01A1)
- Takeda Pharmaceutical Company
- Boehringer Ingelheim
- Janssen Pharmaceutica
- Amgen
- UCB
- Pfizer
- Takeda Pharmaceuticals U.S.A.
- American College of Gastroenterology (DK109384)
This publication has 13 references indexed in Scilit:
- Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative ColitisClinical Gastroenterology and Hepatology, 2020
- Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE OpenAlimentary Pharmacology & Therapeutics, 2019
- Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programmeAlimentary Pharmacology & Therapeutics, 2019
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical TrialsClinical Gastroenterology and Hepatology, 2019
- 796 – Real-World Effectiveness of Tofacitinib in Ulcerative Colitis; a Multi-Center StudyGastroenterology, 2019
- Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and PreventionInflammatory Bowel Diseases, 2018
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2017
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisNew England Journal of Medicine, 2012
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007